English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Approved treatment for hepatitis C virus (HCV) with all‐oral direct‐acting antivirals (DAA) therapy is now entering into its fourth year; however, little has been reported on the real‐world clinical (decompensated cirrhosis [DCC] and hepatocellular carcinoma [HCC]) and economic outcomes. A retrospective cohort analysis of the Truven Health MarketScan Database (2012‐2016) was conducted. In a cohort of 26,105 patients with newly diagnosed HCV, 30% received all‐oral DAA therapy (DAA group) and 70% were not treated (untreated group). Multivariate Cox proportional hazards models were used to compare the risk of developing HCC and DCC, stratified by cirrhosis status. Among patients with cirrhosis (n = 2157), DAA therapy was associated with a 72% and a 62% lower incidence of HCC (hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.15‐0.52) and DCC (HR, 0.38; 95% CI, 0.26‐0.56). Similarly, DAA therapy was associated with a 57% and a 58% lower incidence of HCC (HR, 0.43; 95% CI, 0.26‐0.71) and DCC (HR, 0.42; 95% CI, 0.30‐0.58) in patients with noncirrhotic HCV (n = 23,948). A propensity score–matched cohort of 8064 HCV‐infected patients who had at least a 12‐month follow‐up after HCV treatment was included for economic analysis. For patients with cirrhosis in the DAA group, the mean adjusted liver‐related costs ($1749 vs. $4575;  P  < 0.001) and all‐cause medical costs ($19,300 vs. $33,039;  P  < 0.001) were significantly lower compared with those in the untreated group. The mean adjusted costs were not statistically different between the two groups among patients without cirrhosis.  Conclusion:  In the short term, all‐oral DAA treatment for HCV infection was associated with a decreased risk of developing HCC and DCC, resulting in decreased health care costs, especially in patients with cirrhosis. A longitudinal study is necessary to confirm our findings.

Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States